Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Author Correction: IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity.
Landoni E, Woodcock MG, Barragan G, Casirati G, Cinella V, Stucchi S, Flick LM, Withers TA, Hudson H, Casorati G, Dellabona P, Genovese P, Savoldo B, Metelitsa LS, Dotti G. Landoni E, et al. Among authors: metelitsa ls. Nat Commun. 2024 Jun 18;15(1):5182. doi: 10.1038/s41467-024-49582-6. Nat Commun. 2024. PMID: 38890345 Free PMC article. No abstract available.
Interleukin-15-armored GPC3-CAR T cells for patients with solid cancers.
Steffin D, Ghatwai N, Montalbano A, Rathi P, Courtney AN, Arnett AB, Fleurence J, Sweidan R, Wang T, Zhang H, Masand P, Maris JM, Martinez D, Pogoriler J, Varadarajan N, Thakkar SG, Lyon D, Lapteva N, Mei Z, Patel K, Lopez-Terrada D, Ramos C, Lulla P, Armaghany T, Grilley BJ, Dotti G, Metelitsa LS, Heslop HE, Brenner MK, Sumazin P, Heczey A. Steffin D, et al. Among authors: metelitsa ls. Res Sq [Preprint]. 2024 Apr 3:rs.3.rs-4103623. doi: 10.21203/rs.3.rs-4103623/v1. Res Sq. 2024. Update in: Nature. 2024 Nov 27. doi: 10.1038/s41586-024-08261-8 PMID: 38645165 Free PMC article. Updated. Preprint.
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers.
Steffin D, Ghatwai N, Montalbano A, Rathi P, Courtney AN, Arnett AB, Fleurence J, Sweidan R, Wang T, Zhang H, Masand P, Maris JM, Martinez D, Pogoriler J, Varadarajan N, Thakkar SG, Lyon D, Lapteva N, Zhuyong M, Patel K, Lopez-Terrada D, Ramos CA, Lulla P, Armaghany T, Grilley BJ, Gottschalk S, Dotti G, Metelitsa LS, Heslop HE, Brenner MK, Sumazin P, Heczey A. Steffin D, et al. Among authors: metelitsa ls. Nature. 2024 Nov 27. doi: 10.1038/s41586-024-08261-8. Online ahead of print. Nature. 2024. PMID: 39604730
Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15.
Tian G, Courtney AN, Yu H, Bhar S, Xu X, Barragán GA, Martinez Amador C, Ghatwai N, Wood MS, Schady D, Montalbano A, Reddy S, Roche AM, de la Cerda D, Parsons DW, Di Pierro EJ, Bushman FD, Heczey A, Metelitsa LS. Tian G, et al. Among authors: metelitsa ls. J Immunother Cancer. 2025 Jan 11;13(1):e010156. doi: 10.1136/jitc-2024-010156. J Immunother Cancer. 2025. PMID: 39800376 Free article.
CAR-redirected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanisms.
Zhou X, Wang Y, Dou Z, Delfanti G, Tsahouridis O, Pellegry CM, Zingarelli M, Atassi G, Woodcock MG, Casorati G, Dellabona P, Kim WY, Guo L, Savoldo B, Tsagaratou A, Milner JJ, Metelitsa LS, Dotti G. Zhou X, et al. Among authors: metelitsa ls. Nat Cancer. 2024 Nov;5(11):1607-1621. doi: 10.1038/s43018-024-00830-0. Epub 2024 Oct 1. Nat Cancer. 2024. PMID: 39354225
A milestone method to make natural killer T cells.
Metelitsa LS. Metelitsa LS. Nat Biotechnol. 2024 May 14. doi: 10.1038/s41587-024-02243-x. Online ahead of print. Nat Biotechnol. 2024. PMID: 38744945 No abstract available.
Author Correction: Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results.
Heczey A, Xu X, Courtney AN, Tian G, Barragan GA, Guo L, Amador CM, Ghatwai N, Rathi P, Wood MS, Li Y, Zhang C, Demberg T, Di Pierro EJ, Sher AC, Zhang H, Mehta B, Thakkar SG, Grilley B, Wang T, Weiss BD, Montalbano A, Subramaniam M, Xu C, Sachar C, Wells DK, Dotti G, Metelitsa LS. Heczey A, et al. Among authors: metelitsa ls. Nat Med. 2024 Apr;30(4):1210. doi: 10.1038/s41591-024-02799-w. Nat Med. 2024. PMID: 38195754 No abstract available.
IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity.
Landoni E, Woodcock MG, Barragan G, Casirati G, Cinella V, Stucchi S, Flick LM, Withers TA, Hudson H, Casorati G, Dellabona P, Genovese P, Savoldo B, Metelitsa LS, Dotti G. Landoni E, et al. Among authors: metelitsa ls. Nat Commun. 2024 Jan 2;15(1):89. doi: 10.1038/s41467-023-44310-y. Nat Commun. 2024. PMID: 38167707 Free PMC article.
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results.
Heczey A, Xu X, Courtney AN, Tian G, Barragan GA, Guo L, Amador CM, Ghatwai N, Rathi P, Wood MS, Li Y, Zhang C, Demberg T, Di Pierro EJ, Sher AC, Zhang H, Mehta B, Thakkar SG, Grilley B, Wang T, Weiss BD, Montalbano A, Subramaniam M, Xu C, Sachar C, Wells DK, Dotti G, Metelitsa LS. Heczey A, et al. Among authors: metelitsa ls. Nat Med. 2023 Jun;29(6):1379-1388. doi: 10.1038/s41591-023-02363-y. Epub 2023 May 15. Nat Med. 2023. PMID: 37188782 Clinical Trial.
51 results